Gastrointestinal Drugs Advisory Committee
Committee Meeting October 16, 2012, from 8 a.m. to 5 p.m. (Day 2 of 2)
Agenda: The Committee will discuss the safety and efficacy of new drug application (NDA) 203441, with the proposed trade name GATTEX (teduglutide) for subcutaneous injection, by NPS Pharmaceuticals, Inc, for the proposed indication of treatment of adult patients with short bowel syndrome (SBS).
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment